Ivermectin Role in Covid-19 Clinical Trial

Phase 4

Completed

• Conditions: Covid19
• Interventions: Drug: ivermectin; Drug: Placebo; Drug: hydroxychloroquine

• Registration Number: NCT04746365
• Lead Sponsor: Elaraby Hospital

Brief Summary

Because ivermectin is being used to treat COVID-19 with insufficient evidence, the investigator conducted a randomized clinical trial to investigate the efficacy and safety of ivermectin in comparison to hydroxychloroquine and placebo in severe COVID-19 patients. The study was conducted in Shebin-Elkom teaching hospital and recruited patients from December 6, 2020, to January 31, 2021.

Detailed Description

This study is an adaptive, randomized, double-blinded, controlled trial to evaluate the safety and efficacy of therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a single-center trial that will be conducted in Shebin Elkom teaching hospital. The study will be a series of 3-arm comparisons between two different investigational therapeutic agents (Ivermectin and Hydroxychloroquine) and a placebo. There will be interim monitoring to allow early stopping for futility, efficacy, or safety. Because of the possibility that background standards of supportive care may evolve/improve over time as more is learned about the successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized participants. An independent data and safety monitoring board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms.

Study Timeline

• Study Start: 2020-12-06
• Primary Completion: 2021-01-31
• Status Verified: 2021-02
• Study Completion: 2021-02-06
• Study First Submitted: 2021-02-06
• Study First Submitted QC: 2021-02-08
• Last Update Submitted: 2021-02-08
• Study First Posted: 2021-02-09
• Last Update Posted: 2021-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.
2. Understands and agrees to comply with planned study procedures.
3. Agrees to the collection of OP swabs and venous blood per protocol.
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment.
5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other
6. Severe cases according to WHO definition.

Read More

Exclusion Criteria

1. ALT/AST > 5 times the upper limit of normal.
2. Mortality within 12 hours of admission.
3. Pregnancy.
4. Anticipated transfer to another hospital within 24 hours.
5. Allergy to any study medication commercial or public health assay in any specimen prior to randomization.
6. Mechanically ventilated on admission

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ivermectin	ivermectin	ivermectin was given as a total daily dose of 36 mg on days 0, 3, 6. The daily dose was divided into 3 equal doses of 12 mg (2 tablets) every 8 hours
Placebo	Placebo	Unlabelled standard treatment according to the clinical condition of patients
hydroxychloroquine	hydroxychloroquine	hydroxychloroquine was given as 200 mg (one tablet) every 12 hours for 5 days

Primary Outcome Measures

Name	Time	Method
Reduction in the WHO ordinal scale of clinical status by at least two points	14 days	The ordinal scale consists of 7 points, the maximum score is 7 which indicates a worst outcome, while the minimum score is 1 which indicates a better outcome
Time to discharge	within 14 days	time to discharge to home after no more need for hospitalization

Secondary Outcome Measures

Name	Time	Method
Mortality	14 days	All-causes mortality

Trial Locations

Locations (1)

Shebin-Elkom teaching hospital; 🇪🇬 Shibīn Al Kawm, Menoufia, Egypt